Aegis Capital Corp. in a $10.35 Million Follow-On Public Offering of Signal Genetics, Inc.
Blank Rome represented Aegis Capital Corp. in a $10.35 million follow-on public offering of Signal Genetics, Inc., an emerging commercial stage, molecular diagnostic company focused on providing innovative diagnostic services that help physicians make decisions concerning the care of their patients suffering from cancer. The transaction closed on February 17, 2015.